Guggenheim downgraded 2seventy Bio to Neutral from Buy with no price target after the company announced a “perhaps overdue” strategic restructuring to prioritize the growth of Abecma, streamline pipeline development, and cut costs. However, operating expenses remain “substantial,” which the firm sees increasing the risk of potential future dilutive financing activities without meaningful pipeline catalysts, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TSVT:
- 2seventy Bio CEO Leschly to step down after identification of successor
- 2seventy Bio:U.S. revenue for Abecma ‘may be’ less than $470-$570M prior view
- 2seventy Bio to reduce workforce by 40% for $130M + in savings in FY24-FY25
- 2seventy Bio announces strategic restructuring of business operations
- 2seventy Bio and JW Therapeutics to expand therapy R&D partnership